My own analysis plus what I have gleaned from othe
Post# of 154483
(Total Views: 592)
Posted On: 09/07/2021 5:36:56 PM
My own analysis plus what I have gleaned from others about 13d’s zoom call……………
There was nothing new in their presentation and one and one half hours on a holiday evening was bad form as well as the unprofessional way one was late, one was driving and one did not even bother to show up.
The condescending approach to Q&A was insulting and the lack of any insight as to how they would fund ongoing overhead and trials was telling.
"Rosenbaum mentions Rentrak again what he doesn't say is that the board threw him out of the CEO position.
Rosenbaum says they have no interest in aligning with big pharma. Earlier in the broadcast Patterson said they did.
Beaty says Buyersstrike are putting out hit pieces and the 13d are not aligned in anyway. The 13d communiques (hit pieces) certainly have commonalities.
Errico says that the problems at Electrocore were due to a bad CEO and a bad Chairman of the Board. His brother JP Errico (a 13d member) was that CEO.
At least Rosenbaum admits how tenuous their attempted takeover of Cytodyn"
Seriously shouldn't really have to state this, because we all should know 13d's are what they are and that is not good for us as investors.
No serious people on any of the boards I have been on (8 so far) doubt the science of this molecule.
Where we are at this point in time is getting this molecule across the finish line for the first of what we believe will be many indications.
The current CEO and his team are getting us closer and closer to our goal.
There is a group comprised of former employees, contract players and disgruntled investors who want to replace the current team (management and BOD).
Only after due diligence, did I take the leap of faith and put my trust (and money) into a "pre-revenue" startup bio tech (then more and more past the point of good sense).
Changing the current team for the 13d's at this point would be precipitous and foolhardy at best.
There was nothing new in their presentation and one and one half hours on a holiday evening was bad form as well as the unprofessional way one was late, one was driving and one did not even bother to show up.
The condescending approach to Q&A was insulting and the lack of any insight as to how they would fund ongoing overhead and trials was telling.
"Rosenbaum mentions Rentrak again what he doesn't say is that the board threw him out of the CEO position.
Rosenbaum says they have no interest in aligning with big pharma. Earlier in the broadcast Patterson said they did.
Beaty says Buyersstrike are putting out hit pieces and the 13d are not aligned in anyway. The 13d communiques (hit pieces) certainly have commonalities.
Errico says that the problems at Electrocore were due to a bad CEO and a bad Chairman of the Board. His brother JP Errico (a 13d member) was that CEO.
At least Rosenbaum admits how tenuous their attempted takeover of Cytodyn"
Seriously shouldn't really have to state this, because we all should know 13d's are what they are and that is not good for us as investors.
No serious people on any of the boards I have been on (8 so far) doubt the science of this molecule.
Where we are at this point in time is getting this molecule across the finish line for the first of what we believe will be many indications.
The current CEO and his team are getting us closer and closer to our goal.
There is a group comprised of former employees, contract players and disgruntled investors who want to replace the current team (management and BOD).
Only after due diligence, did I take the leap of faith and put my trust (and money) into a "pre-revenue" startup bio tech (then more and more past the point of good sense).
Changing the current team for the 13d's at this point would be precipitous and foolhardy at best.
(15)
(0)